Clinical Trial

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-04-03; most recent amendment 2025-12-19.
Status change: Recruiting → Not Yet Recruiting 2023-04-04
Status change: Not Yet Recruiting → Recruiting 2017-07-14
Trial Details
NCT Number NCT03104569
Lead Sponsor Hepatopancreatobiliary Surgery Institute of Gansu Province
Conditions Cholangitis
Enrollment 100 participants
Start Date 2026-04-01
Primary Completion 2028-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-26